Finance

Vaccine replace for Covid-19: DCGI approves Dr. Reddy & # 39; s Lab on people with the Sputnik V vaccine

vaccine-replace-for-covid-19-dcgi-approves-dr-reddy-39-s-lab-on-people-with-the-sputnik-v-vaccine

GV Prasad, Co-Chair and MD, DRL said, "This is a significant development that will allow us to begin clinical trial in India and we are determined to introduce a safe and effective vaccine to fight the pandemic." (AP photo)

Dr. Reddys Laboratories and the Russian Direct Investment Fund announced on Saturday that they had received approval from the Indian Drug Control General to conduct a phase 2/3 adaptive human clinical trial for Sputnik vaccines in India. The city-based drug maker said in a press release that this will be a multicenter, randomized controlled trial that will include a safety and immunogenicity study.

GV Prasad, Co-Chair and MD, DRL said, "This is a significant development that will allow us to begin clinical trial in India and we are determined to introduce a safe and effective vaccine to fight the pandemic."

Kirill Dmitriev, CEO of RDIF, said, “We are excited to be working with Indian regulators and, in addition to the data from the Indian clinical trial, we will provide safety and immunogenicity studies from the Russian Phase 3 clinical trial. These data will further bolster the clinical development of the Sputnik V vaccine in India. "

Get live stock quotes from BSE, NSE, the US market and the latest in net asset value, portfolio of mutual funds, calculate your tax with the Income Tax Calculator and know the top gainers, top losers and best equity funds in the market. Like us on Facebook and follow us on Twitter.

Financial Express is now in the telegram. Click here to join our channel and stay up to date with the latest news and updates from Biz.

0 Comments
Share

Steven Gregory